Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,894 across all filing types
Latest filing 2020-06-12 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
国信证券股份有限公司作为天士力医药集团股份有限公司独立财务顾问在充分尽职调查和内核基础上出具的承诺函
Regulatory Filings Classification · 95% confidence The document is a commitment letter from Guosen Securities Co., Ltd. acting as an independent financial advisor for a major asset restructuring transaction involving TianShiLi Pharmaceutical Group Co., Ltd. It includes statements about due diligence, compliance with regulations, and confidentiality measures. The document is short (869 characters) and does not contain financial statements or detailed financial data. It is a professional opinion and assurance letter related to a major asset restructuring, not the restructuring report itself. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2020-06-12 Chinese
董事会关于本次重大资产出售相关主体不存在《关于加强与上市公司重大资产重组相关股票异常交易监管的暂行规定》第十三条不得参与任何上市公司重大资产重组情形的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the board of directors of TianShiLi Pharmaceutical Group Co., Ltd. regarding a major asset sale and compliance with regulations related to major asset restructurings. It specifically addresses the absence of any parties involved in the transaction who are prohibited from participating in major asset restructurings under regulatory provisions. The document does not contain financial statements or detailed financial data but rather a compliance and regulatory explanation related to a major asset restructuring transaction. It is not a full report, earnings release, or audit report, but rather a regulatory announcement related to a transaction. Given the content and nature, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-06-12 Chinese
董事会关于本次重大资产重组前十二个月内购买、出售资产的说明
Capital/Financing Update Classification · 95% confidence The document is a statement from the board of directors of a listed company regarding asset transactions within the last 12 months prior to a major asset sale. It details the purchase and sale of assets related to a significant asset restructuring, referencing regulatory requirements for major asset reorganizations. The document does not contain full financial statements or comprehensive financial performance data, nor is it a report like an annual or interim report. It is a specific disclosure related to a major asset sale transaction, which fits best under the category of Capital/Financing Update (CAP), as it involves significant changes in the company's asset structure and financing implications.
2020-06-12 Chinese
独立董事关于评估机构的独立性、评估假设前提的合理性、评估方法与评估目的的相关性以及评估定价的公允性的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent opinion from the independent directors of TianShiLi Pharmaceutical Group Co., Ltd. regarding the independence of the appraisal agency, the reasonableness of appraisal assumptions, the relevance of appraisal methods to the appraisal purpose, and the fairness of the appraisal pricing related to a major asset sale transaction. It references laws and regulations, the independence and objectivity of the appraisal, and concludes on the fairness of the transaction price. The document is short (1080 characters) and focuses on an independent director's opinion on an asset appraisal related to a transaction, not a full audit report or annual report. It is not a certification letter but an independent opinion on a specific transaction's appraisal. This fits best under Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to transactions, excluding full annual reports. Therefore, the classification is AR with high confidence. Q2 2020
2020-06-12 Chinese
关于重大资产出售一般风险提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by the company regarding a major asset sale transaction. It includes details about the transaction parties, the percentage of shares to be sold, the nature of the transaction as a major asset restructuring, references to board meeting approvals, and risk warnings related to insider trading and regulatory approvals. The document does not contain financial statements or detailed financial performance data, nor is it a full report. It is a risk warning announcement related to a significant asset sale, which fits the category of Capital/Financing Update (CAP) as it concerns a major transaction affecting the company's capital structure and assets. The document length is short (1118 characters), and it is not merely an announcement of a report publication but a substantive announcement about a transaction and its risks.
2020-06-12 Chinese
内蒙古建中律师事务所关于天士力医药集团股份有限公司分拆所属子公司天士力生物医药股份有限公司至上海证券交易所科创板上市的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm regarding the proposed spin-off and listing of a subsidiary company on the Shanghai Stock Exchange's Science and Technology Innovation Board (科创板). It extensively discusses the legal compliance, qualifications, financial conditions, independence, and disclosure related to the spin-off listing. The document references specific regulatory requirements, audit reports, board meeting resolutions, and legal statutes. It is not a financial report, earnings release, or a simple announcement but a comprehensive legal opinion supporting a corporate action related to capital market activities. This type of document is best classified under Capital/Financing Update (CAP) because it pertains to a significant financing and capital market transaction (spin-off and listing of a subsidiary). It is not a Regulatory Filing (RNS) because it is a substantive legal opinion, not a generic regulatory announcement. It is not a Proxy Solicitation or Voting Results document, nor an M&A filing. The length and content confirm it is a full legal opinion on a capital market transaction.
2020-06-12 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.